New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA For Advanced Melanoma
December 08, 2014 at 16:21 PM EST
Amgen (NASDAQ: AMGN) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, ...
